Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase 1/2 3Phase 3 2

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Thoracic 1Head & Neck 1Breast 1

Conditions

Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × bemarituzumab × Clear all
NCT07146919 2026-04-23

ANGELICA

Centre Leon Berard

Phase 1/2 Withdrawn
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05325866 2026-02-04

FORTITUDE-301

Amgen

Phase 1/2 Completed
260 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05322577 2025-12-05

FORTITUDE-103

Amgen

Phase 1/2 Active not recruiting
72 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡